Epidemiology of HIV infection in multitransfused hemophilic patients in France. French Study Group in Hemophilia [published erratum appears in Nouv Rev Fr Hematol 1987;29(6):436] NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Epidemiology of HIV infection in multitransfused hemophilic patients in France. French Study Group in Hemophilia [published erratum appears in Nouv Rev Fr Hematol 1987;29(6):436]

Nouv Rev Fr Hematol. 1987;29(4):211-4. Unique Identifier : AIDSLINE MED/88096479
Sultan Y; Centre d'Accueil et de Traitement des Hemophiles, Hopital; Cochin, Paris, France.

Abstract: A total of 27 hemophilia centers treating patients all over France responded to a questionnaire about the progression of HIV infection in multitransfused patients. Information from 2,049 hemophilic patients was collected. The prevalence of HIV infection in French hemophiliacs was 48%, the same as the percentage in 1985, demonstrating that the methods of viral inactivation of concentrates and screening of blood donors are efficient. However, the number of patients with AIDS increased from 14 to 26 and patients dead from opportunistic infection from 47 to 14 in 1 year. There is also evidence of clinical symptoms of AIDS-related complex and biological symptoms of immunodeficiency in this population of seropositive French hemophiliacs.
Keywords: Acquired Immunodeficiency Syndrome/*EPIDEMIOLOGY/ETIOLOGY Blood Transfusion/*ADVERSE EFFECTS France Hemophilia/*COMPLICATIONS/THERAPY Human Questionnaires JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDepidemiology/etiologybloodtransfusion/KWDadverseeffectsfrancehemophilia/KWDcomplications/therapyhumanquestionnairesjournalarticle
880430
M8840378

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .